Inhibikase Therapeutics (IKT) Return on Capital Employed (QoQ) (2021 - 2026)

Inhibikase Therapeutics (IKT) Return on Capital Employed (QoQ) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Inhibikase Therapeutics 407.51 Mn 237.14 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 1,038.00
Dec 31, 2025 2,338.00
Sep 30, 2025 -1,256.00
Jun 30, 2025 -969.00
Mar 31, 2025 1,617.00
Dec 31, 2024 112,429.00
Sep 30, 2024 -87,972.00
Jun 30, 2024 -6,879.00
Mar 31, 2024 -7,814.00
Dec 31, 2023 -4,226.00
Sep 30, 2023 -2,749.00
Jun 30, 2023 -1,155.00
Mar 31, 2023 239.00
Dec 31, 2022 -1,151.00
Dec 31, 2021 -1,244.00
Sep 30, 2021 49.00
Jun 30, 2021 2,549.00